Neumann is director of the Center for the Evaluation of Value and Risk (CEVR) at Tufts Medical Center. Crummer is a research assistant at CEVR. Kaltenboeck is a principal and head of prescription drug ...
The US Food and Drug Administration (FDA) accepts a wide variety of applications into its Emerging Technologies Program (ETP), and is not just focused on continuous manufacturing, said Joel Welch, ...
The final guidance also specifies that FDA's emerging technology team will work in partnership with the Office of Compliance and Office of Regulatory Affairs "to conduct review, on-site evaluation, ...
N-Sorb leverages Aptar CSP Technologies’ proven 3-Phase Activ-Polymer™ platform technology to address the pressing issue of N-nitrosamine impurities in pharmaceuticals. These impurities, classified as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results